Q2 2018

Filed Aug 14, 2018 · 10-Q · 45 days after period end · 0001493152-18-011762

Q2 2018 · 10-Q

Revenue—

Net Income

-$671.43K

N/M vs Q2 2017

EPS Diluted

-$0.07

N/M vs Q2 2017

Operating Income-$685,125N/M

Operating Cash Flowderived-$344,755N/M

Same quarter

Metric	Q2 2018	Q2 2017	Q2 2016	Q2 2015
Revenue	—	$0.00	$0.00	$0.00
Net Income	-$671.43K	-$451.09K	-$524.49K	-$109.12K
EPS Diluted	-$0.07	-$0.04	-$0.08	-$0.02

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protagenic Therapeutics, Inc.\new · CIK 1022899 · Engraved from SEC EDGAR